Trial Profile
A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine in Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Feb 2022
Price :
$35
*
At a glance
- Drugs PA83 FhCMB (Primary) ; Aluminium hydroxide
- Indications Anthrax
- Focus Adverse reactions; First in man
- Sponsors Fraunhofer USA Center for Molecular Biotechnology
- 10 Feb 2022 Results published in the Vaccine
- 10 May 2016 Status changed from active, no longer recruiting to completed.
- 17 Jun 2015 Status changed from recruiting to active, no longer recruiting,as reported by ClinicalTrials.gov.